<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513928</url>
  </required_header>
  <id_info>
    <org_study_id>B1621005</org_study_id>
    <nct_id>NCT01513928</nct_id>
  </id_info>
  <brief_title>A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects</brief_title>
  <official_title>A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-04937319 In Overweight And Obese Otherwise Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the pharmacokinetics of three different formulations of
      Pf-04937319
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pf-04937319: Maximum plasma concentration (Cmax)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pf-04937319: Time for Cmax (Tmax)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pf-04937319: Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pf-04937319: Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pf-04937319: terminal half-life (T1/2)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PF-06455349: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PF-06455349: Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PF-06455349: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PF-06455349: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - âˆž)]</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PF-06455349: Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0 - 96 hours post dose</time_frame>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pf-04937319</intervention_name>
    <description>Formulation A) Pf-04937319 50 mg - administered as tablet</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pf-04937319</intervention_name>
    <description>Formulation B) Pf-04937319 50 mg - administered as capsule</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pf-04937319</intervention_name>
    <description>Formulation C) Pf-04937319 50 mg - administered as capsule</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive.
             Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead ECG or clinical laboratory tests.

          -  Subjects of childbearing potential must agree to use a highly effective method of
             contraception throughout the study and for at least 28-days after the last dose of
             treatment.

          -  Body Mass Index (BMI) of 23 to 33 kg/m2 and a total body weight &gt;=50 kg (110 lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (excluding untreated seasonal allergies).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  A positive urine drug screen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1621005&amp;StudyName=Astudy%20To%20Compare%20The%20Pharmacokinetics%20Of%20Different%20Formulations%20Of%20PF-04937319%20In%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>relative bioavailability</keyword>
  <keyword>formulation comparison</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

